Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 3/20 | 0.55 |
| ▸ | GRM2 | Q14416 | 15/20 | 0.54 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2901244 | 1.00 | FADS1 (0.55) | FADS1GRM2PRSS12HTR2A | |
| SCHEMBL2893947 | 0.89 | FADS1 (0.55) | FADS1GRM2PRSS12HTR2A | |
| SCHEMBL2893278 | 0.88 | FADS1 (0.60) | FADS1GRM2HTR2A | |
| SCHEMBL13955909 | 0.88 | FADS1 (0.60) | FADS1GRM2HTR2A | |
| SCHEMBL2896672 | 0.88 | FADS1 (0.56) | FADS1GRM2PRSS12 | |
| SCHEMBL2896673 | 0.88 | FADS1 (0.56) | FADS1GRM2PRSS12 | |
| SCHEMBL2892189 | 0.86 | FADS1 (0.55) | FADS1GRM2PRSS12HTR2A | |
| SCHEMBL2892191 | 0.86 | FADS1 (0.55) | FADS1GRM2PRSS12HTR2A | |
| SCHEMBL8234201 | 0.86 | GRM2 (0.58) | FADS1GRM2PRSS12HTR2A | |
| SCHEMBL2915828 | 0.86 | FADS1 (0.60) | FADS1GRM2PRSS12HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | claimed |
| EP-1994016-A2 | 5-PHENYL-3-BENZYL-OXAZOLIDIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| WO-2007078523-A2 | 5-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | WO | claimed |
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | FADS1 4353/4885GRM2 3/4885PRSS12 2209/4885 |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | FADS1 4353/4885GRM2 3/4885PRSS12 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.